Singapore, 5 July 2025 — Atlantis Bioscience, a leading biomedical distributor in Singapore, recently collaborated with Izon Science to participate in the Asia Pacific Societies for Extracellular Vesicles (ASPEV) 2025, held at One Farrer Hotel, Singapore from 3–4 July 2025. The two-day event brought together leading researchers and innovators in extracellular vesicle (EV) science across Asia-Pacific, focusing on translational applications in diagnostics, therapeutics, and regenerative medicine.

ASPEV 2025 is a prestigious joint initiative uniting leading EV societies across China, Japan, Korea, Taiwan, Australia/New Zealand, India, and Malaysia. This year’s conference was hosted by the Society for Clinical Research and Translation of Extracellular Vesicles Singapore (SOCRATES) and promised to be a milestone event in EV science and translational research.

Izon Science is a global leader in nanoparticle characterisation and extracellular vesicle isolation. Its flagship platform, the Exoid, is the only commercially available instrument using Tunable Resistive Pulse Sensing (TRPS) technology — enabling accurate, single-particle measurements of size, concentration, and zeta potential. Izon’s innovative qEV isolation columns and Automatic Fraction Collector (AFC) also support scalable and reproducible EV purification workflows, making them a gold standard for EV research across academia and industry.

Engaging the EV Community: Conversations, Custom Solutions & Collaboration

Throughout ASPEV 2025, Atlantis Bioscience and Izon Science co-hosted a vibrant and well-attended booth, which saw overwhelming interest from scientists, clinicians, and biotech leaders. Attendees stopped by to explore cutting-edge solutions for EV isolation and characterisation, and to connect with our technical team for workflow insights and troubleshooting advice.

The event also served as a platform to announce ongoing collaborations and share insights on emerging trends — including the use of EVs in wound healing, drug delivery, cosmetics, nutrition, and regenerative therapies.

Dr Haoyu Xiong, Business Development Manager, APAC at Izon Science, delivered a presentation on scaling up EV purification using the qEV PurePath workflow — a customisable and clinically driven solution developed to support the transition from early-stage EV data to therapeutic-grade isolates. His inspiring speech reinforces Izon’s commitment to advancing translational workflows in EV-based therapies.

We also brought excitement to the booth with our exclusive blind box giveaways and curated goodie bags, which sparked smiles and valuable networking moments throughout both days.

Shared Vision: Accelerating Exosome Research with Impact

Both Atlantis Bioscience and Izon Science share a vision to advance exosome research beyond the bench and enable meaningful clinical outcomes. With growing regulatory scrutiny and the need for high-quality, reproducible data, researchers are increasingly turning to technologies like TRPS to characterise EVs at a single-particle level.

“The future of EV research lies in precision and scalability,” said a spokesperson from Atlantis. “We’re proud to work alongside Izon to support researchers working on real-world applications in cell and gene therapy, personalised medicine, and beyond.”

The Promise of EV-Based Therapeutics

EVs — particularly exosomes — have emerged as powerful vehicles for targeted delivery of RNA, proteins, and small molecules. Their low immunogenicity, natural origin, and biological communication roles make them attractive candidates for therapeutic applications. However, challenges in standardised isolation, characterisation, and scale-up still remain.

Atlantis Bioscience aims to help researchers overcome these hurdles by providing complete workflow solutions tailored to translational needs across Southeast Asia, including Singapore, Thailand, and Malaysia.

End-to-End EV Workflow Solutions from Atlantis Bioscience

At ASPEV 2025, Atlantis showcased its comprehensive EV product portfolio, including:

• Cell Culture for EV Extraction: EV-depleted FBS, exosome-depleted HPL, and chemically defined media (coming soon).
• Sample Concentration: qEV TFF system for pre-isolation concentration.
• EV/Exosome Isolation: qEV SEC columns, AFC for automation, and large-scale solutions like Zenco and Dxter.
• Characterisation: Exoid (TRPS technology) for single-particle analysis, and Biotium ExoBrite™ stains for imaging and assays.

With over 1,000 curated products across the EV, nanoparticle, and advanced cell therapy space, Atlantis Bioscience continues to be a lifetime partner to researchers throughout the Asia-Pacific and beyond.

To learn more about our EV tools, imaging dyes, and ongoing promotions, visit: www.atlantisbioscience.com or download our EV workflow solution booklet.